Objective：To investigate the clinical features of chronic hepatitis B patients after stopping nucleos（t）ide analogues and related factors for hepatitis B relapse. Methods：We investigated 73 chronic hepatitis B patients who withdrew nucleos（t）ide analogues and analyzed the reasons for withdrawal and related factors for hepatitis B relapse. Results：Those who stopped lamivudine had longer relapse time compared with combination therapy（P=0.031）. Among patients with total treatment duration more than 24 months，those who stopped entecavir had longer relapse time compared with combination therapy（P=0.048），and lower HBV DNA level while relapsed compared with lamivudine（P=0.039）. The COX proportional hazards model analysis showed that total treatment duration was the risk factor for hepatitis B relapse after stopping nucleos（t）ide analogues with patients who did not achieve cessation criteria. Conclusion：Most patients stopped nucleos（t）ide analogues without achieving cessation criteria. There was a still high relapse rate among patients in spite of they had achieved cessation criteria. The longer antiviral treatment duration was associated with a short time recurrence with those who did not achieve cessation criteria.